Your browser doesn't support javascript.
loading
More than half of patients with a rheumatic disease or immunologic condition undergoing methotrexate treatment reside in states in which the overturning of Roe v. Wade can jeopardize access to medications with abortifacient potential.
Starzyk, Kathryn; Hoffman, Veena; Su, Zhaohui; Meng, Roger; Bhartia, Mudit; Curhan, Gary; Yoshida, Kazuki; Paulus, Jessica K.
Affiliation
  • Starzyk K; OM1 Inc., Boston, MA.
  • Hoffman V; OM1 Inc., Boston, MA.
  • Su Z; OM1 Inc., Boston, MA.
  • Meng R; OM1 Inc., Boston, MA.
  • Bhartia M; OM1 Inc., Boston, MA.
  • Curhan G; OM1 Inc., Boston, MA.
  • Yoshida K; OM1 Inc., Boston, MA.
  • Paulus JK; OM1 Inc., Boston, MA.
Arthritis Rheumatol ; 75(2): 328-329, 2023 02.
Article in En | MEDLINE | ID: mdl-36369393
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Abortifacient Agents / Rheumatic Diseases / Immune System Diseases Limits: Humans Country/Region as subject: America do norte Language: En Journal: Arthritis Rheumatol Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Abortifacient Agents / Rheumatic Diseases / Immune System Diseases Limits: Humans Country/Region as subject: America do norte Language: En Journal: Arthritis Rheumatol Year: 2023 Document type: Article Country of publication: